DuPont de Nemours, Inc. (DD) unveiled its Liveo C6‑8XX Liquid Silicone Rubber (LSR) series on February 3 2026, adding a new USP Class VI (C6) line of medical‑grade, two‑part silicone elastomers to its healthcare portfolio. The five‑product family—Liveo C6‑830, C6‑840, C6‑850, C6‑860 and C6‑870—covers Shore A hardnesses from 30 to 70 and is engineered for both non‑implant and short‑term implant medical devices.
The series delivers a pot life exceeding three days, lower viscosity, and improved rheology compared with earlier C6 products, enabling faster, more consistent molding cycles and greater design flexibility for complex components. All variants meet USP Class VI, selected European Pharmacopoeia (EP) requirements, REACH SVHC limits (< 0.1 % w/w), and ISO 10993 testing, positioning the LSRs as a reliable, high‑performance material for manufacturers seeking enhanced processability without compromising safety or regulatory compliance.
The launch comes amid a growing demand for advanced materials in the medical device sector, where manufacturers are pushing for lower‑viscosity, high‑flow elastomers to support liquid injection molding of intricate, minimally invasive devices. DuPont’s new LSRs address this trend by offering superior flow characteristics and extended pot life, giving customers the ability to produce more complex parts with reduced cycle times. The product also competes with offerings from Dow, Evonik and Momentive, and its regulatory compliance profile gives it a competitive edge in markets that require strict USP and ISO certification.
DuPont’s healthcare strategy has accelerated in recent years through acquisitions such as Spectrum Plastics and Donatelle Plastics, which expanded its injection‑molding and LSR capabilities. The Liveo C6‑8XX series reinforces this focus, expanding the company’s Class VI portfolio and strengthening its position in the short‑term implant and non‑implant segments. The launch signals DuPont’s intent to capture a larger share of the high‑growth medical‑device materials market, where demand for compliant, high‑performance elastomers is projected to rise sharply.
Mateo Chirinos Palacios, global product marketing manager for DuPont Healthcare Solutions, said the new LSR series “has been engineered to provide flexibility and reliability for medical device manufacturers. With better flow during molding and a pot life of greater than three days, this new LSR series enables improved processability and more complex designs, among many other benefits.” The company expects the series to drive adoption in both existing and new customer segments, supporting its broader goal of expanding revenue in the healthcare materials space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.